SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 8^th Annual MASH Investor Conference on Monday, October 7, 2024 at 11:30 AM ET.

The webcast of the presentation will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang 
89bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact: 
Sheryl Seapy
Real Chemistry
This email address is being protected from spambots. You need JavaScript enabled to view it.